High triglyceride natural history, prognosis and complications

Revision as of 20:20, 18 July 2016 by Luke Rusowicz-Orazem (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Triglyceride Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Biochemistry

Physiology

Clinical Correlation

Triglyceride Laboratory Test

High Triglyceride

Epidemiology and Demographics
Pathophysiology
Causes
Prognosis and Complications
History and Symptoms
Physical Examination

Low Triglyceride

Epidemiology and Demographics
Pathophysiology
Causes
Prognosis and Complications

Treatment

Lifestyle modification

Medical Therapy

Primary Prevention

Secondary Prevention

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

High triglyceride natural history, prognosis and complications On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of High triglyceride natural history, prognosis and complications

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on High triglyceride natural history, prognosis and complications

CDC on High triglyceride natural history, prognosis and complications

High triglyceride natural history, prognosis and complications in the news

Blogs on High triglyceride natural history, prognosis and complications

Directions to Hospitals Treating Triglyceride

Risk calculators and risk factors for High triglyceride natural history, prognosis and complications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Unclear Association of Hypertriglyceridemia with Atherosclerosis and Cardiovascular Events

It remains unclear if there is an independent association between hypertriglyceridemia and adverse cardiovascular outcomes [1][2]. The ascertainment of any independent association between hypertriglyceridemia and clinical outcomes is confounded by the fact that hypertriglyceridemia is associated with so many atherosclerotic risk factors including obesity, diabetes and insulin resistance, metabolic syndrome, the presence of other dyslipidemias associated themselves both with high triglycerides and atherosclerosis (e.g. mixed hyperlipidemia, low HDL (hypoalphalipoproteinemia), Familial dysbetalipoproteinemia (type III hyperlipoproteinemia), etc.), high levels of small, dense LDL and finally high levels of apolipoprotein B (apoB).

For example, the relationship among hypertriglyceridemia, atherosclerosis, and apoB is complex. Specifically, those forms of hypertriglyceridemia associated with high levels of apoB, but not those associated with low levels of apoB, are associated with atherosclerosis.[3]

Pancreatitis

Hypertriglyceridemia can be associated with pancreatitis when the triglyceride levels are markedly elevated (i.e. when the triglyceride concentration is greater, and often very much greater, than 1000 mg/dl or 12 mmol/l).

Acute Treatment of Pancreatitis Due to Hypertriglyceridemia

The patient should be treated with intravenous insulin at 0.1 to 0.3 units/kg/day to maintain glucose of 150 to 200 if the following are present:

  • The patient cannot tolerate apheresis
  • Apheresis is not available,
  • Serum glucose >500 mg/dL
  • The insulin should be discontinued when the triglyceride level drops to below 500 mg/dl

Secondary prevention of hypertriglyeride induced pancreatitis consists of a low-carbohydrate diet and gemfibrozil 600 mg PO BID.

Xanthoma

Photograph of patient's hands showing multiple xanthoma tendinosum

References

  1. Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007; 9:110-5.
  2. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008; 19:355-61.
  3. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010; 6:335-46.

Template:WH Template:WS